Depression

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, review a case of a 26-year-old male patient who was recently diagnosed with treatment resistant depression

New Drug Application to be submitted for MDD in late 2022, with separate filing for PPD planned for early 2023. 

How to regulate circadian rhythms and regulate mood using dark therapy.

Sidney Zisook, MD, shares insights into defining depression diagnosis.

Bringing science to the practice of psychiatry has been the personal goal of Sheldon H. Preskorn, MD—the Educator of the Year.

James L. Knoll IV, MD, shares insights from his decades in forensic psychiatry, where he has treated some of the criminal justice system’s most difficult and dangerous patients.

Caplyta shows promise as a monotherapy for patients with bipolar I or bipolar II disorder experiencing a major depressive episode

At the Annual Psychiatric Times World CME Conference, an all-star lineup of presenters will share their latest research. Check out this preview of the full agenda.

What can be done to help patients turn painful memories into opportunities for posttraumatic growth?

A hypnotic might be a good option for augmenting depression treatment, but which hypnotic has the best evidence for efficacy?

After a string of disappointing results, mirtazapine gets another look in a recent study.

How can clinicians distinguish between ordinary grief, depression, and prolonged grief disorder?

What toll does trauma take on police officers, firefighters, and EMT workers?

What are the risk factors for and prevalence overweight and obesity in patients with first-episode drug-naïve major depressive disorder?

A clinical review of an effective approach for treatment-resistant depression.

What will psychiatric practice look like in the year 2030?

Could the emerging field of epigenetics hold the key to catching postpartum depression before it happens?

What are the greatest unmet mental health needs in the United States today? Recent statistics from the Centers for Disease Control may hold the answers.

Blue light is associated with a host of physical health maladies, including obesity, diabetes, and cancer. But what does it do to patients with depression or bipolar disorder?

A deep dive into the history, side effects, and efficacy of a controversial drug.

A rare robust finding from a study on bipolar depression.

If approved, SLS-002 would be only the second approved product for ASIB.

Apathy occurs throughout the spectrum of neurocognitive disorders, but it is easy to mistake for other conditions, like depression. How can clinicians identify apathy, and treat it?

Research confirms COVID-19’s negative impact on Americans’ mental health.